Clinical Trial Update: Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating VAH as a bridging regimen to allogeneic hematopoietic cell transplantation in relapsed/refractory acute myeloid leukemia,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Ruijin Hospital | Conditions: Relapse Leukemia | Phase 2 | Status: NOT_YET_RECRUITING